AlphAIAlphAI — Financial news for AI agents
healio.comOCT 282 min read$LLY

Retatrutide confers greater decreases in HbA1c, weight vs. Ozempic in type 2 diabetes

Eli Lilly's retatrutide showed greater HbA1c reduction (2.2%) and weight loss (19.5%-20.9%) vs. Novo Nordisk's Ozempic (1.8%, 9.4%) in a phase 3 trial for type 2 diabetes. Retatrutide also improved cholesterol, triglycerides, and blood pressure. Common side effects included diarrhea and nausea. Eli Lilly plans to present full results at a future conference.

Original reporting
healio.com
Published Oct 28, 2026, 4:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 5:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Retatrutide confers greater decreases in HbA1c, weight vs. Ozempic in type 2 diabetes — source image
Source · healio.com
Decision brief

The 30-second read

$LLYBullishMed
01

Why it matters

The trial data provides the first head‑to‑head efficacy comparison, a key catalyst for Lilly's diabetes pipeline.

02

Market read

New efficacy data may shift market expectations for diabetes treatments and affect related stocks.

03

What to watch

Regulatory approval timeline and reimbursement decisions could delay commercial impact.

Relevance 7/10Novelty 8/10Timing: immediate release today

Background

Retatrutide, a GLP‑1/GIP/glucagon triple agonist, is being positioned against existing GLP‑1 drugs like Ozempic.

Company-level read

Ticker impact

$LLYBullishHigh confidence
Context

Eli Lilly's phase 3 trial shows retatrutide reduces HbA1c and weight more than Ozempic, a new efficacy data release.

Expected impact

likely upward pressure as investors price in potential market share gain.

Evidence & confidence

First disclosure of superior efficacy may lead to higher valuation and future sales.

Market effects

Sector

strengthens the GLP‑1 diabetes drug segment and may pressure competitors.

Regional

U.S. and global diabetes markets could see increased demand for triple‑agonist therapies.

Global

high for biotech and pharma investors worldwide.

Counterpoint

What could challenge this read

Skeptics may question long‑term safety and pricing, potentially limiting upside.

Key entities

  • company
    Eli Lilly

    Pharmaceutical company developing retatrutide.

  • company
    Novo Nordisk

    Maker of Ozempic, the comparator drug.

Read at source← All news

StoryEli Lilly’s retatrutide beats Ozempic in Phase 3 diabetes trial

Also covered by

6 outlets

Related articles

OCT 28
$LLYMed

Eli Lilly Stocks Rise After Retatrutide's Head-to-Head Trial Results

Eli Lilly's shares rose 1.21% to $1,297.37 after its experimental drug retatrutide showed superior weight loss and blood sugar control in a head-to-head trial with Ozempic. The 80-week trial in type 2 diabetes patients showed retatrutide patients lost 47.4 pounds on average, compared to 20.9 pounds with Ozempic. However, more retatrutide patients discontinued treatment due to adverse events. Lilly's market value is $1.22 trillion with a P/E ratio of 44.08, indicating high investor expectations.

finance.yahoo.com2 min
OCT 28
$LLYMed

Lilly’s ‘triple-G’ drug tops Novo’s Ozempic in diabetes trial

Eli Lilly's retatrutide outperformed Novo Nordisk's Ozempic in a Phase 3 trial, showing greater blood sugar reduction and weight loss. The highest dose of retatrutide reduced blood sugar by 2.2 percentage points, compared to Ozempic's 1.8 points. Retatrutide also demonstrated significant weight loss, with the highest dose resulting in a 21% reduction, but had higher discontinuation rates due to side effects.

finance.yahoo.com2 min
OCT 28
$LLYHigh

Retatrutide Tops Semaglutide on A1C, Weight in Head-to-Head Trial

Eli Lilly's retatrutide showed greater reductions in HbA1c and weight loss compared to Novo Nordisk's semaglutide in a phase 3 trial. Retatrutide lowered HbA1c by 2.2 points and achieved 19.5-20.9% weight loss, while semaglutide achieved 1.8 points and 9.4% weight loss. Adverse events led to higher discontinuation rates with retatrutide.

ajmc.com3 min
OCT 28
$NVOMedAI 8/10

Novo Nordisk, Eli Lilly, Pfizer, Roche, Amgen, and Viking Therapeutics are developing new weight-loss drugs

Novo Nordisk, Eli Lilly, Pfizer, Roche, Amgen, and Viking Therapeutics are developing new weight-loss drugs. Novo Nordisk is working on CagriSema and amycretin, while Eli Lilly has Foundayo, retatrutide, and EloraTZP. Roche's enicepatide showed 15.5% weight loss in mid-stage trials, with late-stage tests planned for 2027. Amgen's MariTide is in late-stage trials for obesity and related conditions.

qz.com2 min
OCT 28
$LLYHigh

Lilly’s next-gen drug outperforms Ozempic in weight loss trial

Eli Lilly's experimental drug retatrutide showed greater weight loss and blood sugar control than Novo Nordisk's Ozempic in a late-stage trial. Retatrutide's 9mg and 12mg doses led to an average weight loss of 44.3 and 47.4 pounds, respectively, compared to 20.9 pounds with Ozempic. Lilly plans to seek regulatory approval for retatrutide, which could shift treatment paradigms for type 2 diabetes and obesity if approved.

thenews.com.pk2 min